A federal court setback on childhood vaccine policy has left the White House weighing legal options against electoral risks, as it navigates pressure from its MAHA base alongside broader public support for immunization programs.
The Trump administration has yet to appeal a federal court ruling that halted key elements of its childhood vaccine overhaul.
The hesitation leaves the White House caught between its Make America Healthy Again (MAHA) base and broader political calculations ahead of November's midterm elections.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
On March 16, U.S. District Judge Brian Murphy ruled that the CDC acted
In the IDSA’s statement, attorney for the plaintiffs Richard Hughes IV of Epstein Becker Green said, “This ruling is a momentous step toward restoring science-based vaccine policymaking. The judge recognized that the actions of Secretary Kennedy and the Advisory Committee on Immunization Practices are not grounded in science and that they are destructive. We are thrilled that the court has discarded the baseless vaccine schedule changes made by Secretary Kennedy and is blocking the Advisory Committee on Immunization Practices from doing further damage to vaccine policy."2
Two weeks after the ruling, the administration has taken no steps to challenge it, a notably slower response than in other cases where the Trump administration has moved aggressively to contest unfavorable court decisions.
In one recent instance, the Justice Department appealed a ruling blocking construction of a White House ballroom within hours of the decision being issued.
Four senior administration officials told Reuters the path forward remains undecided, with options under consideration including, appealing the ruling on the committee removals, accepting the ruling and reconstituting the committee in line with the judge's requirements, or some combination of both.1
Kennedy is said to still be weighing his options, and the White House did not respond to questions about whether an appeal was planned.1
The hesitation reflects a difficult balancing act for the administration as it prepares for midterm elections. Kennedy's MAHA constituency, seen as a key part of the coalition that helped deliver Trump's 2024 victory, expects a fight, but public support for the administration's vaccine agenda is limited.1
Republican strategist Jeff Grappone described the situation as a delicate needle to thread, with the White House trying to preserve its full coalition heading into November. Policy consultant Abby McCloskey, who has worked for Republicans, said accepting the ruling and pivoting away from vaccines could allow the administration to focus on more voter-friendly MAHA priorities like children's diets and technology use. "They should take the block and move on," she said.1
According to Reuters, two sources say the White House has already begun shifting its health policy focus away from vaccines toward issues like healthy eating in recent weeks.
The administration retains a 60-day window to appeal the decision. Reconstituting the vaccine advisory committee, however, would not be a quick process, a University of North Carolina public health professor who served on the original panel said the vetting process for new members typically takes a year or more. One committee member, Dr. Robert Malone, said he has already left the committee after speaking with Kennedy.1
MAHA advocacy groups are pushing for an appeal. Tony Lyons, president of MAHA Action, called the ruling a short-term setback and expressed confidence in the administration's commitment to the movement's goals.1
Children's Health Defense, the anti-vaccine group Kennedy co-founded, has attempted to insert itself into the case and said it would appeal the ruling, though it would need formal party status to do so.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
